Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 9/20 | 0.62 |
| ▸ | FABP2 | P12104 | 1/20 | 0.57 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325861 | 0.90 | PPARA (0.56) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL4000649 | 0.84 | PPARA (0.47) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL11545612 | 0.83 | PPARA (0.71) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL4653170 | 0.82 | PPARA (0.69) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL1045831 | 0.82 | PPARA (0.69) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| Methylamine SCHEMBL27865949 | 0.82 | PPARA (0.63) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL3844599 | 0.82 | PPARA (0.69) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL247466 | 0.81 | PPARA (0.68) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL7823197 | 0.81 | PPARA (0.63) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL12777729 | 0.81 | PPARA (0.68) | PPARAMEN1KMT2ACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | claimed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | claimed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | claimed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| EP-2821402-B1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2019-08-21 | — | — | EP | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| EP-0358724-A4 | COMPOUND, COMPOSITION AND METHOD FOR THE REDUCTION OF LIPIDS THE MODIFICATION OF THE AFFINITY OF HEMOGLOBIN FOR OXYGEN AND THE PREVENTION OF PLATELET AGGREGATION. | LALEZARI IRAJ (US) | 1990-06-05 | — | — | EP | disclosed |
| US-4921997-A | Method of synthesis and novel compounds for pharmaceutical uses | MONTEFIORE MEDICAL CENTER (US) | 1990-05-01 | — | — | US | disclosed |
| EP-0358724-A1 | COMPOUND, COMPOSITION AND METHOD FOR THE REDUCTION OF LIPIDS THE MODIFICATION OF THE AFFINITY OF HEMOGLOBIN FOR OXYGEN AND THE PREVENTION OF PLATELET AGGREGATION | LALEZARI, Iraj (US) | 1990-03-21 | — | — | EP | disclosed |
| WO-1989012622-A1 | METHOD OF SYNTHESIS AND NOVEL COMPOUNDS FOR PHARMACEUTICAL USES | LALEZARI IRAJ (US) | 1989-12-28 | — | — | WO | disclosed |
| WO-1988010113-A1 | COMPOUND, COMPOSITION AND METHOD FOR THE REDUCTION OF LIPIDS THE MODIFICATION OF THE AFFINITY OF HEMOGLOBIN FOR OXYGEN AND THE PREVENTION OF PLATELET AGGREGATION | LALEZARI IRAJ (US) | 1988-12-29 | — | — | WO | disclosed |
| US-4053626-A | CHOLESTEROL LEVEL-LOWERING PHENOXYACETIC ACIDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-10-11 | — | — | US | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
| US-3992386-A | 4(Quinolyl)phenoxy alkanoic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PPARA 4163/4885MEN1 544/4885KMT2A 921/4885 |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | PPARA 775/4885MEN1 507/4885KMT2A 546/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PPARA 4070/4885MEN1 636/4885KMT2A 929/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PPARA 4070/4885MEN1 636/4885KMT2A 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.